Article Text

Download PDFPDF
Diagnostic Implications of p16 Expression in Serous Papillary Endometrial Cancer
  1. Itamar M. Netzer, MD*,
  2. Hedwiga Kerner, MD,
  3. Ludmila Litwin, MD,
  4. Lior Lowenstein, MD* and
  5. Amnon Amit, MD*
  1. *Gynecologic Oncology Unit, Department of Gynecology and Obstetrics, and
  2. Pathologic Institute, Rambam Medical Center, Haifa, Israel.
  1. Address correspondence and reprint requests to Itamar M. Netzer, MD, Department of Gynecology and Obstetrics, Rambam Medical Center, 8 Haaliya St, Haifa, Israel. E-mail: I_netzer{at}rambam.health.gov.il.

Abstract

Objective: The purpose of this study was to examine whether the degree of expression of the p16 protein in serous papillary endometrial cancer bears a prognostic significance. The secondary objective was to establish the value of p16 immunohistochemical staining as an adjunct to diagnosis.

Study Design: Archived paraffin blocks holding specimens from the uteri of 31 serous papillary and 31 endometrioid endometrial carcinoma patients were recut and restained for p16 and p53.

Results: Overexpression of p16 was found in 78% of the serous papillary patients versus 36% of the endometrioid patients. p16 was not found to be an independent prognostic factor in serous papillary endometrial carcinoma.

Conclusions: Although p16 was not found to have prognostic significance in serous papillary endometrial carcinoma, it may be valuable as a diagnostic adjunct in histologically ambiguous tumors.

  • Endometrial carcinoma
  • Serous papillary
  • Biomarkers
  • Prognosis

Statistics from Altmetric.com

Footnotes

  • The authors declare that there are no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.